Amphotropic murine leukemia virus (MLV) replicates in cells from various mammalian species, including humans, and is a potential contaminant in MLV vector preparations for human gene transfer studies. Mus dunni fibroblasts are routinely used for amplification and detection of contaminating virus. We have recently characterized an amphotropic MLV mutant lacking the 75-bp viral enhancer elements and spontaneous MLV-(RCMV) recombinants that have acquired cytomegalovirus (CMV) transcription elements. Both of these viruses replicate in specific human cell types. To test
Amphotropic murine leukemia virus was originally isolated from feral mice and found to replicate in cells from various mammalian species, including humans. 1, 2 The env gene of isolate 4070A 3 was subsequently used for transduction of primate cells with the newly developed murine leukemia virus (MLV) vectors. 4, 5 Human gene transfer studies frequently use MLV-based vectors with amphotropic host range to introduce and express markeror therapeutic genes. 6 Recombinant, replication-competent amphotropic murine leukemia virus is a potential contaminant and safety risk in these vector preparations. 7, 8 Replication-competent virus can potentially arise at all stages of vector production by recombination between vector and packaging constructs or host DNA, such as endogenous retroviruses. The probability of such a recombination and the exact genotype of the recombinant virus depends on the design of the production process and the nature of packaging-and vector constructs. 9 Considerable progress has been made during the past years to exclude the generation of replication competent virus (for a recent review see Ref. 10) . The US Food and Drug Administration (FDA) has recently released 'Guidance on testing for replication competent retrovirus in retroviral vector-based gene therapy products and during follow-up of patients in clinical trials using retroviral vec- tor'. 11 As a routine procedure the FDA recommends testing samples of the cell banks, vector supernatant and ex vivo transduced cells by infection on a Mus dunni fibroblast line 12 and subsequent detection in a PG-4 S+LϪ indicator assay.
We used an amphotropic host range mutant of Moloney MLV, MLV-(MOA) (Figure 1 ), to study replication and gene expression of amphotropic MLV in human cells. 13 In brief, the provirus MLV-(MOA) is based on the Moloney-MLV clone 63-2, 14 but contains the (Figure 1 ) is characterized by a deletion that extends from position Ϫ357 to Ϫ150 in the U3 region and removes both enhancer copies at positions Ϫ341 to Ϫ257 and Ϫ266 to Ϫ182. 15 We have demonstrated that amphotropic MLV replication in most transformed human cells tested requires the presence of these 75 bp enhancer elements. 16 However, in specific human fibrosarcoma and lymphoma lines virus replication is possible in the absence of these enhancers. 13 One of these lines, the fibrosarcoma HT-1080 is the basis of the FLY family of packaging cells. 17 In contrast to these human cells, murine NIH/3T3 cells are not permissive for Mo-MLV mutants that lack both 75 bp enhancer elements. 15 In the human breast cancer lines MCF-7 and ZR-75-1, the replication defect of MLV-(MOA)⌬E can be rescued by spontaneous recombination and insertion of the cytomegalovirus immediate-early (IE) promoter and enhancer into the LTR. 16 The resulting virus MLV-(RCMV) consists of a major population RCMV1 and a minor population RCMV2 that differ in the size of the CMV promoter/enhancer region inserted between the MLV U3 and R regions ( Figure 1 ). The replication of both MLV-(MOA)⌬E and MLV-(RCMV) in human cells is restricted to specific sets of cell lines. The generation of similar viruses during production of self-inactivating MLV vectors that delete the viral transcription elements 18 and transcriptionally targeted vectors that replace the viral transcription elements with heterologous elements 19 must be considered, but has not yet been observed.
To address the question whether enhancer-deficient and enhancer-recombinant amphotropic MLV can be amplified with current routine procedures for subsequent detection, we infected Mus dunni fibroblasts with MLV-(MOA)⌬E grown in HT-1080 fibrosarcoma, Ramos B lymphoma or MHH-PREB-1 lymphoma. 13 The CMV promoter recombinant MLV-(RCMV) from MCF-7 and ZR-75-1 cells was also included in this study. 16 MLV-(MOA) from MCF-7 cells was used as positive control. For the infection, virus-containing medium was harvested, filtered and serial dilutions of this medium were tested for virus-associated reverse transcriptase (RT) activity. The actual RT activities were calculated from the linear range of the dilution curve. M. dunni cells (2 × 10 5 ) for infection were plated in a 25 cm 2 culture flask and grown for 24 h. Duplicate cultures were infected with equivalent amounts of virus, corresponding to 10 5 c.p.m. of RT activity. The infected cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, penicillin (100 IU/ml) and streptomycin (100 g/ml) for a period of 22 days to allow virus spread. When cultures reached confluency, the RT activity in the medium was determined as a measure of virus replication and the cells were diluted into fresh medium ( Figure 2) .
Replication of the intact virus MLV-(MOA) was detected 4 days after infection ( Figure 2 , panel 1). Mockinfected cultures remained at background RT levels for the entire experiment. Elevated RT activity in cultures infected with enhancer-deficient MLV-(MOA)⌬E from MHH-PREB-1, HT-1080 and Ramos cells was found between days 8 and 11 after infection ( Figure 2 , panels 4 to 6). The replication kinetics of all three isolates was very similar and independent of the cell line of origin. Replication was delayed for approximately 7 days relative to MLV-(MOA) (Figure 2 ). Once replication became detectable, the replication rate was similar to the rate of MLV-(MOA).
The enhancer recombinant MLV-(RCMV) isolates from MCF-7 and ZR-75-1 human breast carcinoma cells replicated with characteristics similar to MLV-(MOA)⌬E. After a delay of 4 days (ZR-75-1 isolate) to 7 days (MCF-7 isolate) relative to MLV-(MOA), RT activity above mock control level was detectable 8 days (ZR-75-1) and 11 days (MCF-7) after infection ( Figure 2 , panels 2 and 3). Replication rates after the delay were comparable to the replication rate of MLV-(MOA). Thus, the presence of CMV transcription elements in MLV-(RCMV) provides no (MCF-7 isolate) or little (ZR-75-1 isolate) replication advantage over enhancer-deficient MLV-(MOA)⌬E. RT activity in the medium of infected cells reached levels that were at least two orders of magnitude higher than in the corresponding mock control samples (Figure 2) . RT values above 2 × 10 6 c.p.m./ml were not resolved in this experiment.
The relative virus levels in the plateau phase of the culture were determined in serial dilution experiments of culture media harvested at day 22. These data demonstrate that reverse transcriptase activity in the medium of M. dunni cells infected with MLV-(RCMV) from MCF-7 and ZR-75-1 cells reached 44% and 32%, respectively, when compared with the MLV-(MOA) control (100%) (data not shown). Virus-associated RT activity in the culture medium of cells infected with MLV-(MOA)⌬E from HT-1080, Ramos and MHH-PREB-1 cells was reduced to 20%, 23% and 13% of the MLV-(MOA) control (data not shown).
The delayed replication phenotype of both MLV-(MOA)⌬E and MLV-(RCMV) in M. dunni cells suggests that either mutants within the population are selected which have a replication advantage over the major population or that alternatively the virus inoculum, after normalization to RT activity, contained less infectious particles than MLV-(MOA). To determine whether the virus population in M. dunni cells maintains the genotype of the virus inoculum with regard to the U3 region, we isolated virus RNA from the M. dunni culture supernatants at day 11. The oligo dT-primed cDNA generated from these RNAs was used in a PCR to amplify the viral U3-R region with primers FS1 and HR2 (Figure 3 ). The PCR products were resolved on a 5% polyacrylamide gel to detect even small size differences between the viral U3 regions (Figure 3 ). The DNA was visualized by silver staining. In order to identify potential rearrangements within the U3-R regions during replication in M. dunni cells, viral RNA from infected M. dunni cultures ( Figure  3 , lanes 3, 5, 7, 9-11) was compared with samples of MLV-(MOA), MLV-(RCMV) and MLV-(MOA)⌬E ( Figure  3, lanes 2, 4, 6, 8 ) that were used for infection.
As previously reported, 13 the MLV-(MOA) inoculum from MCF-7 cells (Figure 3 , lane 2) yields a characteristic 492 bp major fragment that represents the intact virus and includes two enhancer copies. In addition, a minor population (MOA * ) with a U3 region that is reduced in size by approximately 70 bp is present. This population was previously identified in a human lymphoma culture 13 as spontaneous deletion mutant that has lost one copy of the two 75 bp U3 enhancer elements. Replication The MLV-(RCMV) inoculum from MCF-7 cells contains a major population RCMV1 and a minor population RCMV2 with 780 bp and 520 bp U3-R regions, respectively ( Figure 3, lane 4) . These fragments have previously been sequenced and found to contain different portions Gene Therapy of the CMV immediate-early promoter and enhancer region inserted between the MLV R and U3 region. 16 Replication in M. dunni cells drastically changed the relative abundance of these two populations. The 520 bp RCMV2 was identified as the predominant population in these cells (Figure 3, lane 5) . The MLV-(RCMV) population in ZR-75-1 cells has previously been characterized on the Gene Therapy
Figure 3 RT-PCR analysis of amphotropic MLV RNA from infected Mus dunni fibroblasts. Virus RNA was isolated from the medium of M. dunni cells (Mdun) infected with MLV-(MOA) from MCF-7 cells (MC, lane 3), MLV-(RCMV) from MCF-7 cells (lane 5) or ZR-75-1 cells (ZR, lane 7), MLV-(MOA)⌬E from HT-1080 (HT, lane 9), Ramos (Ra, lane 10) or MHH-PREB-1 cells (MH, lane 11) and mock infected M. dunni cells (mock, lane 1). The virus inocula (lanes 2, 4, 6, 8) with MLV-(MOA) from MCF-7 (lane 2), MLV-(RCMV) from MCF-7 (lane 4) or ZR-75-1 (lane 6) and MLV-(MOA)⌬E from HT-1080 cells (lane 8) were included as control. The oligo dT-primed cDNA was used for PCR amplification of the U3-R region. For isolation of viral RNA cell culture supernatants
were cleared and virions pelleted as described. 13 The pellet was resuspended in 1 (Figure 2, panels 2 and 3) .
The MLV-(MOA)⌬E inoculum from HT-1080 cells yielded a major RT-PCR product of 286 bp (Figure 3, lane  8) . The size reflects the 207 bp deletion that removes the two 75 bp enhancer elements from the LTR in MLV-(MOA)⌬E. As previously established, MLV-(MOA)⌬E from Ramos and MHH-PREB-1 lymphomas produced an U3-R fragment of the same size. 13 A minor 410 bp product is also seen with the proviral plasmid template 13 and hence does not represent a recombinant that arises during culture. M. dunni cells infected with MLV-(MOA)⌬E from HT-1080, Ramos or MHH-PREB-1 cells (Figure 3 , lanes 9 to 11) exhibit the same 286 bp U3-R region as the corresponding virus inoculation samples. No MLV RNA was detected in the mock infected M. dunni culture (Figure 3, lane 1) . We conclude that M. dunni fibroblasts are permissive for replication of amphotropic MLV lacking the 75 bp viral enhancer elements and for recombinants of this virus with heterologous transcription elements.
In current detection procedures for amphotropic MLV, virus amplification in Mus dunni fibroblasts is followed by a S+LϪ titration assay on PG-4 cells. To determine whether this titration assay can be used to detect the recombinant amphotropic virus MLV-(RCMV) and MLV-(MOA)⌬E, we have tested the culture supernatants of infected M. dunni cells from Figure 2 on PG-4 cells ( Table  1) . The assay was performed as described by Haapala et al 20 with serial dilutions of the culture media in an infection volume of 1 ml. We found that both amphotropic recombinant virus types MLV-(RCMV) and MLV-(MOA)⌬E form plaques on PG-4 cells independently of the primary origin of the virus. However, the plaque size (MOA > RCMV > MOA⌬E) was reduced for the recombinant virus types. The virus titers were approximately 2% for MLV-(RCMV) and 0.1% for MLV-(RCMV), when compared with the amphotropic virus MLV-(MOA) (100%). In the same samples, the activity of virion-associated reverse transcriptase (RT) activity (Table 1) was reduced to 16-24% for MLV-(RCMV) and 10-17% for MLV-(MOA)⌬E relative to MLV-(MOA) (100%). The differences in the infectious titers are not equally reflected by the differences in RT activity. The ratio of infectious titer to RT activity is approximately 1.4 for MLV-(MOA), 0.13 for MLV-(RCMV) and 0.012 for MLV-(RCMV). Thus, samples with identical RT activity of MLV-(RCMV) and MLV-(MOA)⌬E contain 9 and 0.9 plaque forming units (p.f.u.), respectively, for every 100 p.f.u. of MLV-(MOA). This may be explained (a) by either reduced virion stability or infectivity of virus recombinants; (b) by plaque formation in only a minor fraction of PG-4 cells infected with recombinant virus; or (c) a mixed virus population.
Amphotropic murine leukemia virus is a potential contaminant and risk factor in preparations of MLV-based vectors for human gene transfer. 8, 11 Replication-competent amphotropic virus may develop at any step of the vector production process by recombination between vector and packaging constructs or host genomic DNA, 13 Similarly, MLV replication under the transcriptional control of the CMV IE promoter is possible in certain human cell lines, but has not been observed in murine NIH/3T3 fibroblasts. 16 Current routine control procedures for detection of amphotropic MLV in vector preparations use a Mus dunni tail fibroblast line for virus amplification. 11 The capacity of these cells for amplification of enhancer-deficient and -recombinant MLV had not yet been determined. As shown, M. dunni fibroblasts are permissive for the amphotropic (4070A) host range recombinant of Moloney MLV, MLV-(MOA). We report here that M. dunni fibroblasts are also permissive for MLV-(MOA)⌬E lacking both copies of the 75 bp transcription enhancer in the U3 region. Replication is delayed for approximately 7 days relative to MLV-(MOA), but proceeds with a rate comparable to MLV-(MOA). The insertion of heterologous enhancers in the MLV U3 region can be excluded for the majority of the virus population. The observed replication delay may result from either the selective replication of a virus subpopulation or alternatively from a reduced infectious titer relative to MLV-(MOA) as is indicated by our titration experiments in Table 1 . Also, there is an apparent discrepancy between the similar replication rates of MLV-(MOA) and MLV-(MOA)⌬E on one hand and the lower RT levels of MLV-(MOA)⌬E in the culture media on the other hand. This suggests that part of the initial MLV-(MOA)⌬E inoculation does not contribute significantly to
Gene Therapy the production of progeny virus, but protects infected cells from superinfection by productive virus.
The MLV-(RCMV) recombinants that include CMV transcription elements in the LTR have the same or similar replication kinetic in M. dunni cells as the enhancerdeficient MLV-(MOA)⌬E. Since the heterologous elements are not required for replication, we observe a selection for RCMV variants within the population that have reduced the size of the U3-R region. It is important to note that consequently, MLV recombinants with heterologous transcription control regions that are amplified and detected in M. dunni cells may not be identical to the original recombinant MLV that is present in the packaging line or the vector preparation. Thus, the characterization of the recombinant virus must not focus on the M. dunni selected population only, but also on the source of the virus material.
Our results demonstrate that MLV replication without the 75 bp U3 enhancer elements is not limited to human cell lines, but is also found in a Mus dunni fibroblast line. Also, the formation of plaques in feline PG-4 cells infected with MLV recombinants indicates viral replication in this cell type and thus allows detection and titration of these viruses in the PG-4 based S+LϪ assay.
